FoliuMed has completed its inaugural soft-gel capsule shipment to Australia, with the company positioning the product as a potential successor to tinctures in the local medical cannabis market.
The company, which operates manufacturing and R&D facilities in Germany alongside cultivation operations in South America, said the capsules give doctors a way to prescribe precise cannabinoid doses to patients — either 25mg of CBD per capsule or 10mg of THC.
FoliuMed has consistently declined to name its Australian customer, though it has since come to light that Althea took delivery of the shipment.
Produced in Germany from pharmaceutical plant extracts cultivated in Colombia under Good Manufacturing Practice standards, the capsules contain the full spectrum of cannabinoids and terpenes.
FoliuMed founder and CEO Oliver Zugel said the soft-gel format has a real chance of displacing tinctures as the preferred delivery method in Australia.
"Soft-gel capsules allow for more precise dosage than other forms of consumption. Additionally, doctors usually do not like to prescribe smokable products. We believe that capsules will eventually replace tinctures if they are offered at a comparable price point."
He said cost continues to be a significant barrier for patients in Australia.
"This is why we are recommending our B2B customers in the different markets we serve offer the capsules at a comparable price point to tinctures, so that choice for the patient becomes simple.
"They get the benefit of precise dosing, discretion, portability and taste masking at the same price they pay for an oral solution."
